Eosinophilic bronchitis: clinical manifestations and implications for treatment

Gibson, P. G.; Fujimura, M.; Niimi, A.
February 2002
Thorax;Feb2002, Vol. 57 Issue 2, p178
Academic Journal
Airway inflammation with eosinophils is now reported to occur not only in asthma but in other airway diseases such as cough variant asthma, chronic cough, atopic cough, episodic symptoms without asthma, allergic rhinitis, and COPD. Although the prevalence of eosinophilic bronchitis (EB) is less than in asthma, the causes, mechanisms and treatment of EB in these conditions appears to be similar to asthma where allergen induced IL-5 secretion and symptoms are readily responsive to inhaled corticosteroids. The prognosis of EB without asthma is not known but it may be a precursor for asthma and, if so, recognition of this syndrome may permit effective treatment and reduction in the rising prevalence of asthma: Induced sputum analysis allows recognition of EB in clinical practice. The place of the asthma treatment paradigm with early and sustained corticosteroid treatment needs to be defined in EB without asthma. Airway wall remodelling can occur in rhinitis, COPD, and cough variant asthma with EB. The mechanisms and long term implications of this complication in EB without asthma need to be clarified.


Related Articles

  • Rates of asthma attacks in patients with previously inadequately controlled mild asthma treated in clinical practice with combination drug therapy: an exploratory post-hoc analysis. Negro, Robert W. Dal; Borderias, Luis; Qiaoyi Zhang; Tao Fan; Sazonov, Vasilisa; Guilera, Magda; Taylor, Stephanie D. // BMC Pulmonary Medicine;2009, Vol. 9, p1 

    Background: Differences could exist in the likelihood of asthma attacks in patients treated with inhaled corticosteroid (ICS), long-acting beta-agonist (LABA), and montelukast (MON) (ICS/LABA/ MON) and patients treated with an inhaled corticosteroid (ICS) and montelukast (MON) (ICS/ MON)....

  • Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. Katial, Rohit K.; Oppenheimer, John J.; Ostrom, Nancy K.; Mosnaim, Giselle S.; Yancey, Steven W.; Waitkus-Edwards, Kelli R.; Prillaman, Barbara A.; Ortega, Hector G. // Allergy & Asthma Proceedings;Jan/Feb2010, Vol. 31 Issue 1, p68 

    Limited information exists comparing fluticasone propionate/salmeterol combination (FSC) versus montelukast (MON) in patients with coexistent asthma and allergic rhinitis. The purpose of this study was to compare the addition of MON to patients receiving FSC on asthma control while experiencing...

  • Healthcare utilisation and costs associated with adding montelukast to current therapy in patients with mild to moderate asthma and co-morbid allergic rhinitis: PRAACTICAL study. dal Negro, Roberto; Piskorz, Peter; Vives, Roberto; Guilera, Magda; Kocevar, Vasilisa Sazonov; Badia, Xavier; Sazonov Kocevar, Vasilisa // PharmacoEconomics;2007, Vol. 25 Issue 8, p665 

    Objective: To evaluate the healthcare resource use and costs associated with adding montelukast to therapy in patients with mild to moderate persistent asthma and co-morbid seasonal allergic rhinitis whose asthma is inadequately controlled by their current asthma...

  • Asthma: clinical assessment.  // Thorax;Dec2004 Supplement, Vol. 59, p50 

    The article presents some papers related to clinical assessment of asthma. There is currently great interest in developing non-invasive measures of airway inflammation in asthma. Proposed markers of airway inflammation and or oxidative stress in asthma include the exhaled gases, nitric oxide...

  • Highlights from this issue. Bush, Andrew; Pavord, Ian // Thorax;Jul2012, Vol. 67 Issue 7, p568 

    An introduction is presented in which the editor discusses various reports within the issue on topics including an approach to modify severe airways disease, treatment with topical nasal corticosteroids of children suffering from allergic rhinitis, and studying the epidemiology of chronic...

  • Review: Adults who require inhaled corticosteroids benefits from a moderate starting dose.  // ACP Journal Club;Nov/Dec2004, Vol. 141 Issue 3, p72 

    The article addresses the question as to what is the optimum starting dose in patients with asthma not treated by inhaled corticosteroids (ICSs). The article adds that In patients with asthma who require inhaled corticosteroids, an initial high dose improves FEV but does not differ from moderate...

  • Inhaled Corticosteroids in Childhood Asthma: Long-Term Effects on Growth and Adrenocortical Function. Salvatoni, Alessandro; Piantanida, Elena; Nosetti, Luana; Nespoli, Luigi // Pediatric Drugs;2003, Vol. 5 Issue 6, p351 

    Inhaled corticosteroids (ICS) are the most potent of all the available inhaled treatments, and are effective medications for long-term control of asthma. However, their use in children is limited by the risk of systemic adverse effects. Although results reported in the literature on the adverse...

  • Is there more than one inflammatory phenotype is asthma? O'Donnell, R. A.; Frew, A. J. // Thorax;Jul2002, Vol. 57 Issue 7, p566 

    The article discusses whether there is more than one inflammatory phenotype in asthma. But there are some problems in asthma investigations. Most asthmatic patients recruited to these studies either had severe disease or were on some form of corticosteroid therapy, raising concerns about...

  • Relation between duration of smoking cessation and bronchial inflammation in COPD. Lapperre, I. S.; Postma, D. S.; Gosman, M. M. E.; Snoeck-Stroband, J. B.; Ten Hacken, N. H. T.; Hiemstra, P. S.; Timens, W.; Sterk, P. J.; Mauad, T. // Thorax;Feb2006, Vol. 61 Issue 2, p115 

    Background: Chronic obstructive pulmonary disease (COPD) is associated with airway inflammation. Although smoking cessation improves symptoms and the decline in lung Function in COPD, it is unknown whether bronchial inflammation in patients with established COPD varies with the duration of...


Read the Article


Sign out of this library

Other Topics